print_label | resize_label

Welcome to the
Zoladex prostate cancer information centre

In the UK, prostate cancer is the most common type of cancer in men, with around 47,200 new cases diagnosed in 2015. 1

This website gives you all the information you need about the prostate cancer treatment Zoladex (goserelin), a type of treatment known as luteinising hormone-releasing hormone analogues (LHRHa’s).

Zoladex branding image

The Zoladex patient information leaflet (PIL) is available to download here:

For more information about:

Reporting of side effects

Like all medicines, Zoladex can cause side effects, although not everybody gets them.

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme, Website: www.mhra.gov.uk/yellowcard. By reporting side effects you can help provide more information on the safety of this medicine.

Side effects can also be reported to AstraZeneca by visiting https://aereporting.astrazeneca.com

AstraZeneca does not control the content of any external websites 


  1. Cancer Research UK: Prostate cancer incidence statistics:
    https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/prostate-cancer#heading-Zero
    (Last accessed January 2019).

GB-15121. Date of Preparation: June 2019